Lexicon Pharmaceuticals, Inc. (LXRX) Earnings Call Transcript & Summary

November 5, 2026

NASDAQ US Health Care Pharmaceuticals earnings 55 min

Earnings Call Speaker Segments

Lisa DeFrancesco

executive
#1

Thank you, operator. Good morning, everyone, and welcome to the Third Quarter 2026 Earnings Call. With me today are Dr. Mike Exton, Lexicon's Chief Executive Officer and Director; Dr. Craig Granowitz, Senior Vice President and Chief Medical Officer; and Scott Coiante, Senior Vice President and Chief Financial Officer. This morning, Lexicon put out a press release announcing our financial results for the third quarter of 2026, and you can find it on our website at www.lexpharma.com as well as through our SEC filings. A webcast of this call, together with a slide presentation, is also available on our website. During today's call, we'll go over the information in that release, give a corporate update, and then spend the rest of the time answering your questions. Before we get started, I want to remind you that we'll be making forward-looking statements, including statements about the safety, efficacy, clinical development, regulatory status, and therapeutic and commercial potential of sotagliflozin, pilavapadin, LX9851, and our other drug programs, as well as about our business generally. This call may include forward-looking statements regarding our growth and future operating results, the discovery and development of our drug candidates, strategic alliances and intellectual property, and other matters that aren't historical facts or information. A variety of risks could cause our actual results to differ materially from those expressed or implied in such forward-looking statements, and we point you to our most recent annual report on Form 10-K and other SEC filings for detailed information about those risks. I'd now like to hand the call over to Mike Exton. Mike?

Mike Exton

executive
#2

Thank you, Lisa. Hello, everyone, and I appreciate you being with us today. With 2026 drawing to a close — a year in which Lexicon has shown tremendous focus and pursued strategic evolution — I'd like to call attention to the considerable strides we've taken throughout the business. To begin with HCM: we finished enrolling patients in our phase III SONATA-HCM trial. The baseline characteristics capture the wide range of patients receiving HCM treatment today, and in our view this sets the study up to assess SOTA in non-obstructive HCM, where substantial unmet need persists, as well as in obstructive HCM, where numerous patients still have symptoms even with the treatment options currently available. A KCCQ baseline of 59 is notable because it points to a population with substantial symptoms and a meaningful opportunity for improvement. Overall, we're quite pleased with how SONATA-HCM has enrolled, and we expect to share top-line data in Q1 of 2027. Now on ZYNQUISTA: we continue to make good progress toward resubmitting the NDA for type 1 diabetes, and that submission will be supported by fresh prospective safety findings from the investigator-initiated STENO1 study. We're very happy with the STENO1 safety results—DKA rates were low and in line with standard of care, and also with the background rate seen among T1D patients in Denmark. It's worth recalling why this is important. For individuals with type 1 diabetes, insulin is still the sole therapy that lowers glucose, and despite current pumps and sensors, roughly just one out of five adults achieves the 7% A1C target. Much of our recent attention has, quite reasonably, gone toward supplying the extra safety data the FDA asked for, yet we should not overlook the robust efficacy findings from our phase III inTandem program. When assessing ZYNQUISTA's overall profile, those findings carry equal weight. Taken as a whole, we believe the inTandem efficacy results together with the new STENO1 safety data provide ZYNQUISTA a convincing benefit-risk profile and a solid basis for our NDA resubmission. That resubmission is currently in preparation. Because STENO1 was launched by investigators and never built for regulatory filing, a substantial amount of work has gone into analyzing, formatting, and getting the data ready for submission and review. The remaining task is bringing this academic dataset up to the regulatory submission standards we have all agreed on. We are completing that work while our conversations with FDA carry on, with the goal of filing the strongest possible package and giving the review the best chance to succeed. This process is taking longer than we first anticipated, but we still expect to finish the resubmission during the first quarter of 2027. Our dedication to people living with type 1 diabetes, and to offering sotagliflozin as a new treatment option, has not changed at all. I feel a great deal of pride in what our team has accomplished to reach this stage, and I want to thank the STENO1 investigators for partnering with us as we pursued an innovative regulatory pathway; now, when it comes to heart failure, our licensee Viatris keeps broadening the worldwide regulatory reach for sotagliflozin, with filings in an increasing number of markets beyond the U.S; and Europe. So far, Viatris has secured approvals in the United Arab Emirates and Bahrain, and it has filed applications in more than a dozen other countries, among them Saudi Arabia, Canada, and Australia. Moving on to LX9851, our first-in-class ACSL5 inhibitor for obesity, the phase I trial that our licensee Novo Nordisk is running is coming along well. In the third quarter, we collected our third $10 million milestone payment of the year from Novo, and we may receive further milestone payments as the program moves ahead; we are highly encouraged by how this promising compound is progressing and glad to watch Novo keep pushing the program forward. Next, on pilavapadin, our confidence in what this agent can do and in its novel AAK1 inhibition mechanism keeps strengthening. Last quarter, I mentioned that we had promising efforts in progress looking at how it might perform in additional high-value indications, and I'm pleased today to reveal a portion of that work, particularly in the areas of obesity and weight management. In preclinical research, pilavapadin has produced notable decreases in body weight, both as a standalone treatment and in combination with semaglutide. While this research remains at an early stage, the findings have given us confidence, and we believe they point to an intriguing fresh opportunity for this program. We look forward to sharing additional details about this as well as other preclinical programs involving pilavapadin. To wrap up, and this matters a great deal, our commitment to running operations excellently and investing with discipline has remained solid while we advance our programs and prepare for upcoming opportunities. In that vein, Rachel Martens was recently appointed Chief Commercial Officer, and we added new marketing and market access leaders to accelerate pre-commercial planning in HCM and T1D. I am very happy with the quality of talent we have and keep drawing to Lexicon, which I think reflects the strength of our programs and the opportunities in front of us; now, before handing the call to Craig, I want to come back to HCM and take a few minutes to explain why we see it as such a compelling opportunity for Lexicon and why sotagliflozin could be uniquely positioned to tackle the substantial unmet need throughout the disease. HCM is a genetic condition marked by adverse cardiac remodeling, which includes myocardial hypertrophy, diastolic dysfunction, and fibrosis. Importantly, that underlying biology constitutes the core pathology in both non-obstructive and obstructive HCM. Although much of the innovation in HCM today focuses on cardiac myosin inhibitors, which act on the heart's contraction mechanism, sotagliflozin follows a fundamentally different path. By inhibiting both SGLT1 and SGLT2, we think sotagliflozin could affect the metabolic and other biological pathways that play a role in diastolic dysfunction in HCM. That difference matters, since the fundamental abnormalities in cardiac structure, function, and metabolism span both forms of HCM, and we believe this means SOTA has the potential to produce meaningful benefits in obstructive as well as non-obstructive disease—exactly what SONATA-HCM is built to assess. For a novel agent such as SOTA, the HCM market represents a large and fast-expanding opportunity. Diagnosis and care for HCM are accelerating across the U.S. and worldwide, but patients continue to deal with a meaningful symptom burden that impacts their daily lives. Right now in the U.S., more than 800,000 patients carry a diagnosis of obstructive or non-obstructive disease, while a much larger number are still undiagnosed today. For nHCM in particular, a gap in treatment remains because no disease-specific therapies hold approval at present, even as that patient population expands rapidly alongside rising obesity and diabetes. There is robust support for a choice that is straightforward, safe, and simple to use for busy and growing cardiology practices. We think that a once-a-day pill form of sotagliflozin—combined with how it works differently from other options and its possible use in both obstructive and non-obstructive HCM—might give doctors and patients a compelling option. With that said, Craig Granowitz, our Chief Medical Officer, will provide further detail on our pipeline. Craig?

Craig Granowitz

executive
#3

Mike, thanks, and good morning to everyone. As Mike mentioned, we still have a phase III trial running called SONATA-HCM in symptomatic HCM patients, and we anticipate top-line data from that study during the first quarter of next year. The design of SONATA-HCM was intended to evaluate SOTA in a wide HCM population reflecting real-world clinical practice. With baseline characteristics for the study now in hand, we are quite pleased that the final population enrolled met that objective. Notably, in both the non-obstructive and obstructive HCM cohorts, demographic and clinical features broadly match what has been reported in prior clinical trials of other agents within those respective patient groups. In the study population overall, the mean baseline KCCQ score came in at 59. The main measure of efficacy for this pivotal trial is how much symptoms improve compared with placebo, assessed through the change from baseline in KCCQ at week 26. In total, SONATA-HCM enrolled 542 patients; at baseline, 440 of them were classified as non-obstructive and 102 as obstructive. The study also allows patients who are on stable background therapies, cardiac myosin inhibitors among them. Evidence from science regarding sotagliflozin continues to build, reinforcing the case for how well it works and its mechanisms in HCM, and providing valuable insight into how dual inhibition of SGLT1 and SGLT2 might be differentiated. In a preclinical mouse model of HCM, SOTA led to better baseline cardiac structure and function measures, diastolic function, hypertrophy, and fibrosis included. Additional studies have demonstrated that SOTA suppresses platelet activation and clot formation, and those effects exceeded what was seen with empagliflozin, an SGLT2 inhibitor — highlighting how much the SGLT1 effects matter when it comes to thrombotic events. At this weekend's upcoming AHA meeting, new investigator-led research will be presented, including work using living human HCM heart tissue in which inhibiting SGLT1 directly lowered myocardial work, and SOTA demonstrated greater potency at higher afterloads than empagliflozin. Another study, in healthy adults given EMPA or SOTA, showed a significant decrease in thrombus formation versus baseline with SOTA, whereas the decrease with EMPA was not significant. We expect that evidence base to keep expanding. The SOTA-CROSS study, which is investigator-initiated and taking place at the University of Pennsylvania, is assessing SOTA in non-obstructive HCM patients—looking at how it affects cardiac function, exercise performance, and quality of life—and completion is now anticipated in 2027. In our view, the results will add scientific and clinical backing for what sets the dual SGLT1/2 inhibitor SOTA apart from SGLT2 inhibitors. On top of that, these HCM-specific findings heighten our enthusiasm as we get closer to the expected SONATA-HCM top-line readout during the first quarter of 2027. Turning to ZYNQUISTA — and building on Mike's earlier points — the inTandem program showed meaningful advantages for individuals living with type 1 diabetes. Those included an HbA1c drop of roughly 0.4 percentage points, about three hours a day gained in time in range, fewer hypoglycemic events, decreased body weight, and lower blood pressure. As a precondition for resubmitting the NDA, the FDA asked for additional prospective data characterizing DKA risk. Following that, we returned to the agency and laid out a path forward built on data from the STENO1 trial. The FDA concurred that STENO1 was capable of supplying the prospective information required for evaluating DKA rates across a sizable population treated with sotagliflozin, on condition that the study delivered enough patient exposure similar to the roughly 200 patient-years of SOTA treatment seen in the inTandem clinical program. And in fact, we have by now satisfied the criteria the FDA set out, including the mandated amount of patient exposure, and we have obtained from STENO the data required to back our resubmission. The efficacy findings from inTandem, paired with the fresh safety data from STENO, leave us more confident about the overall profile of ZYNQUISTA as we get ready to resubmit our NDA. Examining the STENO data more closely, the safety results seen in the trial are encouraging to us. As this slide shows, the DKA rate among patients who received sotagliflozin came to roughly one DKA event for every 100 patient-years of SOTA exposure. That was similar both to the standard of care arm in the STENO1 trial and to the historical rates in Denmark among people with type 1 diabetes. The DKA rate sits well under the rates seen in the SOTA arms of the inTandem studies. To start with the numbers: by the close of August 2026 — the cutoff we're relying on for the FDA resubmission — 496 patients had been randomized to SOTA, while 708 were on the standard of care. That gives us the patient exposure level we agreed upon with the FDA. As Mike mentioned, a lot of work is proceeding with STENO, and we have FDA alignment on the analysis parameters, all aimed at getting the data properly ready for submission and review. The administrative side is taking longer than we initially anticipated, but our confidence in how robust the dataset is hasn't changed, and the headway we're making toward resubmission is encouraging — we now expect that to happen in the first quarter of 2027. Turning next to pilavapadin, our selective AAK1 inhibitor, we continue to investigate what else this program might offer outside its established path in neuropathic pain. We've been examining potential applications for pilavapadin in additional indications, based on its ability to influence biological pathways linked to multiple processes, including nerve transmission involved in gastrointestinal motility. The data shown here provide encouraging early evidence of that potential in obesity and weight management. In this preclinical study, pilavapadin at 10 milligrams per kilogram produced a 14% decrease in body weight after 28 days of treatment. When pilavapadin was administered alongside semaglutide, the mice showed a 31% reduction in body weight, which was greater than the 25% body weight reduction observed with semaglutide alone. Though these findings are early, the results hint that pilavapadin might have activity as a standalone agent and might also deliver incremental benefit when paired with a GLP-1 therapy. We think this potential is especially compelling given how the obesity treatment space keeps changing and the need persists for distinct mechanisms as well as combination approaches; we're still assessing these findings and carrying out further work required to better pin down the opportunity, and we anticipate sharing additional updates as this program moves forward. Now I'll hand things over to Scott to go over our financial results.

Scott Coiante

executive
#4

Thank you, Craig, and good morning. I'll start by reviewing the financial results for the quarter. For the quarter ended September 30, 2026, total revenues came in at $11.3 million, versus $14.2 million in the same period of 2025. Third-quarter 2026 revenues included $10 million of milestone revenue recognized under the Novo Nordisk licensing agreement, along with $1.2 million in net sales of INPEFA. Third-quarter 2025 revenues included $13.2 million of licensing revenue from the Novo agreement, plus $1.0 million in net sales of INPEFA. Research and development expenses were $16.2 million in the third quarter of 2026, compared with $18.8 million in the corresponding period of 2025; that reflects lower external clinical trial expenses following completion of our PROGRESS phase IIb clinical trial in 2025, partly offset by higher SONATA-HCM phase III clinical trial expense in 2026. Selling, general, and administrative expenses were $9.5 million in the third quarter of 2026, compared with $7.6 million in the same period of 2025, reflecting higher employee benefit costs and greater pre-commercialization expenses. Our net loss for the third quarter of 2026 was $14.0 million, or $0.03 per share, versus a net loss of $12.8 million, or $0.04 per share, in the corresponding period of 2025. Net loss for both the 2026 and 2025 third quarters includes non-cash stock-based compensation expense of $3.4 million in each period. As of September 30, 2026, Lexicon held $183.2 million in cash equivalents and short-term investments, compared with $125.2 million in cash equivalents, short-term investments, and restricted cash as of December 31, 2025. As we noted earlier, third-quarter revenue included the third $10 million milestone payment received this year from Novo Nordisk, following achievement of a phase I development milestone for LX9851. We continue to hold our 2026 operating expense guidance of between $100 million and $110 million, with R&D expected between $63 million and $68 million and SG&A expected between $37 million and $42 million, which includes targeted investments in pre-commercial activities. We remain extremely pleased with what we have accomplished financially so far in 2026. As we get ready for several important milestones across our portfolio, we stay focused on preserving the financial flexibility required to support execution and move our key strategic priorities forward, while we keep assessing opportunities to unlock additional value across the portfolio. I'll now hand it back to Mike for closing remarks.

Mike Exton

executive
#5

Thanks, Scott. Looking at the bigger picture, we think Lexicon is heading into a 12-month stretch that could be genuinely transformational, backed by a number of opportunities throughout our cardiometabolic portfolio. On sotagliflozin and HCM, we're getting close to the pivotal phase III SONATA-HCM top-line data readout, which we expect in the first quarter of 2027, and we're continuing our pre-commercial planning and readiness work; in type 1 diabetes, we're pushing toward resubmission of the ZYNQUISTA NDA, backed by additional safety data from STENO1, with that resubmission expected in the first quarter of 2027. Beyond these near-term priorities, the phase I program for LX9851 keeps moving forward, with the potential to open up further development milestone opportunities. With pilavapadin, we have a pain program that's phase III-ready, along with an emerging opportunity in obesity that we're actively looking into. All together, these programs give us multiple potential routes to value creation. We believe the progress we've made speaks to the strength of our science, the breadth of our portfolio, and most importantly, the commitment to creating new opportunities for people living with serious cardiometabolic diseases to live longer, healthier lives. Thanks again for joining us today. We now look forward to taking your questions. Operator, back to you.

Steve Seedhouse

analyst
#6

Morning, everyone. Is my voice coming through clearly?

Lisa DeFrancesco

executive
#7

Yes, apologies for the disruption there, Steve. I'm not certain what caused it, so please go right ahead with your question.

Steve Seedhouse

analyst
#8

Great, thank you very much. I have a couple of questions about the baseline demographics in SONATA. First, I think it's fair to say there's somewhat of an over-representation of non-obstructive HCM in SONATA. There are certainly more patients, but possibly even beyond what the prevalence or the overall demographics of the disease would imply. What do you believe is driving that, in terms of either patient motivation or physician motivation to enroll non-obstructive patients? I also wanted to clarify the percentage on background CMI, which you said is 9%. Is that within the obstructive patients, or is it overall? That's essentially about half of the obstructive patients.

Mike Exton

executive
#9

Yes, thanks, Steve. I appreciate the question. I'll take the first one, and Craig can perhaps take the second. I think non-obstructive patients were strongly represented, which, as you know, reflects what happens in clinical practice. Maybe a bit stronger than what you'd see within the clinic, but we have to remember that these clinical trials are often run by these large academic centers, and those academic centers are where treatments for obstructive HCM are available. I think the need in non-obstructive disease, along with the availability of an approved treatment for obstructive disease, means that was likely a contributor to the preponderance of non-obstructive patients in the trial. Craig?

Craig Granowitz

executive
#10

Steve, that's an excellent question, and I think it ties directly into your second one. When you examine the share of patients receiving a myosin inhibitor, that share is actually identical to the share receiving a CCB. Again, that would strike you as quite different from what the overall U.S. population shows when you compare how many patients are treated with a calcium channel blocker versus a CMI. In the general population, the percentage on a CCB would be far higher. From what I gathered in our conversations with the PIs and the steering committee, the figures—and how they broke down between obstructive and non-obstructive—struck them as unsurprising. As the trial progressed, we kept the steering committee updated on the evolving numbers, and they were emphatic that we should not limit enrollment in either subgroup. If you count the patients receiving a myosin inhibitor, that comes to 49 of the 542 in total. To give you a sense of scale, 50 patients are taking a calcium channel blocker—and again, CCB usage isn't all that different when you look across SONATA and the trials conducted with both AFI and MAVA. Looking at the distribution, it comes to roughly 12% of patients. Let me clarify this once more, since it's a key point—regarding CMI use: every person who was on a CMI had obstructive disease prior to starting the CMI. Keep in mind that the study's inclusion criteria require patients to be on a stable dose of any underlying therapy for, I believe, six months before enrolling in the trial. Every one of those individuals, at the point they started on the CMI, had a gradient that we assume exceeded 50. What strikes me as interesting is the way patients get chosen: at the time they enter SONATA-HCM, some have an outflow tract obstruction and some do not, yet in every case they stay highly symptomatic. My apologies — that response ran quite long. If anything else is bothering you, please break it down for me.

Mike Exton

executive
#11

Yeah.

Steve Seedhouse

analyst
#12

No, no. That—

Mike Exton

executive
#13

Oh, please go ahead, Mike.

Steve Seedhouse

analyst
#14

That was great, I was about to say. Please feel free to add anything if you had something. Though I do have a follow-up question that's unrelated.

Mike Exton

executive
#15

No, go ahead.

Steve Seedhouse

analyst
#16

All right. I'd like to follow up with a question about — well, there's some fascinating data concerning pilavapadin and weight loss. To begin with, what mechanism do you think explains that? And then, given that both pilavapadin and the broader mechanism have been studied in humans before, did any of those clinical trials demonstrate weight loss? I recall there were certain tolerability issues, I believe, at the top dose in the phase II pain programs. Do you believe there's an adequate therapeutic index in humans for obesity or weight-loss indications? Thanks.

Craig Granowitz

executive
#17

Yes. Great question, Steve. To reiterate, this connects with what Mike mentioned in his prepared remarks: we've continued investigating what we see as a genuinely compelling mechanism of action for AAK1. Broadly speaking, AAK1's activity falls into two areas that can be examined. The first is cell surface receptor recycling—the mechanism we believe is at work in neuropathic pain and probably in obesity as well. I'll come back to that in a moment. Beyond that, we have a situation involving the NUMB/NOTCH pathway and how it sets off cell replication, and next year we'll likely share findings on further indications linked to that pathway and to altering the balance between NOTCH and NUMB as it concerns replication versus differentiation of cells. To return to what you asked about the weight loss figures, weight loss was indeed seen in the knockout mice, going back to the initial phenotype. We think the likely mechanism is the same one we've talked about before: there was a modest increase in blood pressure and heart rate in the neuropathic pain program we disclosed, and that's likely linked to the balance between sympathetic and parasympathetic tone, both in the cardiovascular system as it relates to blood pressure and heart rate. Conversely, in obesity you're actually increasing vagal tone, which slows gastric emptying. We think the mechanism behind the weight loss observed in animal models is likely tied to that higher ratio of vagal to sympathetic tone in the GI tract. Turning to the human clinical program, we went back and reviewed the results of our PROGRESS study, and we observed a decrease in body weight in both the 10 milligram and 20 milligram arms. The reduction was larger at 20 than at 10. Again, to your point, we were concerned that this might reflect both some nausea and vomiting as well as genuine weight loss. But in the 10 milligram dose arm, as you remember, the proportion of patients who completed the treatment period matched that of placebo; so we are seeing a weight loss of a couple of kilograms. Again, this covers only eight weeks of treatment, with just six weeks at dose. We do believe — despite the fact that the trial wasn't designed in that manner, this wasn't a population enriched for obesity, and there were no parameters in place to control weight loss or other measures you'd include in a formal obesity trial — that we did observe a reduction in weight loss in the PROGRESS study.

Mike Exton

executive
#18

Yeah, I only wanted to build on what Craig said and remind everyone that the key point regarding the data we're showing on pilavapadin is that, although it's preclinical, it potentially lets us move fairly quickly into a proof-of-concept phase II study in obesity and some of these other indications. It's been our intention, while we wait for some of the critical readouts coming over the next months, to build a data package across a number of indications with AAK1 that really shows the overall value of the mechanism. Then we can think strategically about how we take that forward as we assess some of the other important catalysts that we have going on.

Steve Seedhouse

analyst
#19

Thank you all very much.

Mike Exton

executive
#20

Thanks, Steve.

Joe Pantginis

analyst
#21

Hey, guys. Morning. Appreciate all the details today. Apologies if any of this came up at the start. For a good while on the call, I couldn't hear anything. First, Craig, I was hoping for a bit of profiling on SOTA and HCM, since the field is really growing fast with the CMIs. Aficamten could potentially get approved in both non-obstructive and obstructive, plus the upcoming PDUFA for exercise capacity. So where do you think SOTA fits? Because on top of that, Edgewise confirmed today, regarding their FDA discussions, that they're aiming for fewer echoes or none at all as part of their platform or pivotal pathway. Curious for your quick comments, or whatever you have, on the profiling of SOTA and where it might fit — that's number one. Number two, obviously you're deep in filing prep for T1D, so I'm just curious what you feel is still outstanding to reach completion of the NDA. Thanks a lot.

Mike Exton

executive
#22

Yeah. Thanks, Joe. Maybe I'll take the first point again, and Craig can handle the second one. Look, I think in HCM, this is a big market, and there's going to be ample room for multiple pathways, multiple mechanisms to treat the disease. Clearly, when it comes to treating HCM, it won't be a one-shot-fits-all. Now, where SOTA potentially fits within that paradigm will depend somewhat on how the data reads out, obviously. What we can say is that SOTA potentially has not only efficacy advantages — data pending, of course — but having a once-daily oral medicine with a known safety record immediately opens up broad potential, both from a patient base, but perhaps more importantly from a prescriber base, where a large number of prescribers can potentially use this medicine. Whether that comes as the first choice after beta blockers, or it's used in combination with a sarcomeric agent, we'll be dependent on data, and we'll see as the space evolves. I think having a one and only medicine where we can play our own game, if you like, and let the sarcomeric agents battle against themselves for various risks and benefits is going to be the way we'll play the game. Craig?

Craig Granowitz

executive
#23

Absolutely, Joe — glad to jump back in if anything else needs clarifying regarding the positioning of SOTA against the CMIs or possibly other sarcomeric agents. I'll take the T1D questions. As I believe I noted during the prepared remarks, we only crossed the threshold with STENO1 at the end of August. That's the reason the slide carries that cut date. Naturally, both studies are still enrolling patients, at minimum in the standard of care arm. Enrollment in the MFI arm is complete, though exposure on SOTA keeps building throughout that trial. Our expectation — and the FDA has in fact already communicated this to us — is that during the review they would like to receive data updates; we wanted to confirm that the DKA rate in the SOTA arm had stabilized as well before we filed the package. I've been trying to think of analogs for how to frame this relative to a company-sponsored trial, because keep in mind this was an investigator-initiated study, set up in a way that was never intended to provide the kind of oversight and intensive monitoring you'd find, say, in SONATA-HCM or any other of the regulatory labeling studies; we've genuinely been devoting a great deal of time. In fact, we've directed substantial extra resources toward STENO1 to assist with cleaning the database; it's really about pulling together all the values and satisfying ourselves that the data reporting is accurate — not to the standard of an academic publication, but to the standard of a possible FDA review, which, as you know, are two very different standards. We feel quite confident about the DKA rates we're reporting. The thing is, the FDA will likely also want to examine other parameters to satisfy themselves regarding quality control and oversight, plus many of the other administrative elements that an FDA filing would demand — items like financial disclosures, just a whole host of issues tied to database quality. You run into GDPR issues when it comes to moving data from a European study to a U.S. study that was never designed for that purpose. We had to go back, for instance, and secure changes to the informed consent so the data could be sent out. I mean, this has been a whole host of issues that we've been working through with STENO. We do believe these are in hand, but it has simply taken time. It's a very large data set — close to 2,000 patients — and we just want to ensure we're going to put in the highest quality submission.

Joe Pantginis

analyst
#24

That's really, really useful. I appreciate all the detail.

Mike Exton

executive
#25

Thank you, Joe.

Yasmeen Rahimi

analyst
#26

Morning, everyone. Thanks very much for the excellent updates. There's some genuinely exciting new data from pilavapadin on weight loss. I'd love to get a better understanding — you have a strong partner in Novo that's developing LX9851. Have you had a chance to share any of these pilavapadin data with them? I'd really like to hear what you think about that. My second question concerns HCM; given such a broad distribution of non-obstructive patients, is there a statistical hierarchy that lets you achieve statistical separation in KCCQ with non-obstructive as a sole subgroup? That would be extremely helpful, and I appreciate your perspective. And one final follow-up too.

Mike Exton

executive
#27

Yes, great, Yas. I'll handle the first one and Craig will take the second. Look, we're in fairly regular contact with Novo, as you'd expect — not just regarding LX9851, but there are many things shared across our portfolios; we've had the opportunity to talk about this with a couple of individuals at Novo, though not the wider team. There's definitely interest on their side, as you'd imagine, and we'll keep engaging with them and with others as we build on this and other data. As you'd expect, the chart we showed you here is only one piece of data from that series of studies. There's plenty of other compelling data behind it that is quite robust, and I think it truly demonstrates the value of the AAK1 mechanism. As Craig said, we'll keep building on that; in fact, we have additional data that we'll continue to share when the timing is right to show you that this is a genuinely interesting and important mechanism. Craig?

Craig Granowitz

executive
#28

On patient distribution, Yas, that's a really good question. The truth is, we invested considerable time internally alongside our steering committee, and we brought in some highly respected external academic statistical expertise—many of those names, I believe, you'd certainly recognize—plus regulatory input regarding the population. The firm consensus among everyone involved is that the primary endpoint should stay exactly as it is, using the overall study population. We examined quite a few alternative scenarios aimed at separating the non-obstructive group from the obstructive group. The bottom line, after weighing all that input, is that we chose to leave the primary endpoint unchanged. Within the SAP, I'd note there remain certain matters concerning the hierarchy for the secondary endpoints, which we're reviewing while we keep running additional modeling on the data. Naturally, we'd like to lock down the SAP shortly, though as is true for numerous other companies, finalization of SAPs typically happens just before the database closes—so we definitely have time available, and we're quite confident that this trial's primary endpoint is robust. The fact that we substantially over-enrolled the trial, along with the therapy having been well tolerated throughout treatment, gives us a strong degree of confidence in the power to detect the endpoint in a study showing roughly a 4 to 5-point difference in KCCQ score. So our feeling on that is really positive. We likewise feel very good about how the treatment is proceeding and the patient completion rates. Of course, the trial remains ongoing, so I'd rather not say too much, but thus far we feel quite good regarding the trial's statistics.

Mike Exton

executive
#29

And yes, Yas, that really reflects how we feel about SOTA, about HCM, and about the unmet need present in both obstructive and non-obstructive disease. Making the overall KCCQ delta the primary endpoint in obstructive as well as non-obstructive matters because, as we are seeing here, there remain people on current therapies who are highly symptomatic. The need in obstructive is significant, just as it is in non-obstructive disease. So given the underlying biology and what the market requires, it is important that we truly can address obstructive and non-obstructive disease alike.

Yasmeen Rahimi

analyst
#30

Great. Thanks very much.

Yigal Nochomovitz

analyst
#31

Hello. Thank you. I have a handful of somewhat more granular questions about SONATA-HCM. Craig, I believe you just said there is some flexibility regarding the secondary endpoints and how they are ordered in the hierarchy. Which kinds of factors drive the choice about rearranging secondaries so as to maximize the evidence set? And then, on background diuretic therapy, that is an interesting one regarding how it might affect the outcome. Obviously, you can picture that on the SOTA arm there might be less need for it, while on the control arm you might see more of it, yet that could affect outcomes too. How do you account for that, in terms of adjusting for that potential difference in background diuretic therapy, to ensure a clean readout? Thanks.

Craig Granowitz

executive
#32

Yes, I will take the first question once more, on the secondary endpoints. Once again, the primary endpoint of KCCQ in the overall population will remain the primary. The key secondary of New York Heart in the overall population will remain in place. At present, we will keep the hierarchy as planned down the overall study population, rather than looking at non-obstructive versus obstructive within that hierarchy as you move down the overall parameters. There are several echo parameters and enzyme parameters as secondary or exploratory endpoints. I believe those matter much more for the academic publication than for the regulatory file, and certainly the PIs of the study and we are focused on securing the highest possible tier publication; those are the sorts of things we are discussing in the hierarchy. From a regulatory standpoint and from a claim standpoint, I do not think those will really change appreciably. Turning to the diuretic issue, very few patients in the study are on diuretics. In fact, it does not really even come up, as you can see in the baseline characteristics we have shared and that Dr. Day shared at the Boston HCM meeting about a week or two ago. The largest group of patients on underlying therapy is beta blockers. Roughly 80% of patients are on a beta blocker. As was mentioned earlier, sorry for repeating myself, the next most commonly used agents acting on the cardiovascular system are calcium channel blockers and CMIs, which are similar, both at about 10% of the patients. Diuretic use really is not a significant issue. I mean, there you are talking about patients with severe heart failure, then you are looking at the overall pillars for patients with either HFrEF or HFpEF, but there really is not much use of diuretics in this population.

Yigal Nochomovitz

analyst
#33

Okay, thank you.

Andrew Tsai

analyst
#34

Hello. Good morning, and I appreciate you taking my question. Thanks for the updates. During the International HCM Summit conference, when you shared the phase III baseline patient population for SONATA-HCM, we observed that the obstructive subgroup had a lower baseline KCCQ score than the two other CMI trials did, which points toward a heavier symptom burden at baseline. For the non-obstructive baseline, I believe the KCCQ is perhaps comparable, if not lower. So the bottom line is this: is that a favorable or an unfavorable situation for sotagliflozin to demonstrate a positive benefit on KCCQ in phase III? Thank you.

Craig Granowitz

executive
#35

Yes, excellent question, Andrew. Again, among the other trials published out there, certain ones have baseline KCCQs and certain ones do not. But as you rightly note, the baseline KCCQ for SONATA is 55 in the obstructive group, versus roughly 75 as reported for SEQUOIA. You can also observe that the EF among patients in SONATA, at 67 or 68, is considerably lower than in SEQUOIA and EXPLORER, since they established, as you remember, an enrollment threshold for left ventricular function that is much higher, and that patient group is truly a more hyperdynamic population simply given the entry criteria of the selection. What is interesting in that group, however, is that the BNPs are approximately the same, and the outflow tract obstruction is in fact somewhat larger, as you would anticipate in SEQUOIA and EXPLORER, because the threshold is set at 50 rather than 30 in SONATA. From the feedback our steering committee gave us, they were genuinely pleased with how many women were actually enrolled in the trial, which matters and is meaningful. The fact that you still have patients on a CMI who are symptomatic with obstructive disease — they truly feel this patient group is important. I would contend that the lower baseline KCCQ is actually helpful when trying to show a larger delta in KCCQ, because we know that generally, the lower the baseline KCCQ, the greater the change in KCCQ with treatment.

Andrew Tsai

analyst
#36

Agreed. Yes, thank you. Second, regarding the top-line release in Q1, how much data should we expect you to share? Could you give us a teaser about what kind of efficacy and safety data? What would you otherwise be saving for a medical conference? Thank you.

Craig Granowitz

executive
#37

What we would definitely plan to release, I think, is the top line of the primary and secondary endpoints. Those, I mean, are going to be the key. I think when it comes to a lot of these analyses by these subgroups, we're probably not going to release them, because much of that will require full analysis — particularly when you look at the impact of those with sarcomeric mutations versus those without, and the effects on outcome by underlying medication use; that probably will not be released. We'll release something probably on the top line of safety-related effects in the trial, the major safety effects. Those, I think, are really going to be the critical issues that get released at top line.

Andrew Tsai

analyst
#38

Makes sense. Thank you.

Mike Exton

executive
#39

Thanks, Andrew.

Frank Zhong

analyst
#40

Hi, everyone. Good morning. Frank here, speaking in place of Roanna. I've got a question about the SONATA-HCM trial, which enrolled 440 non-obstructive patients along with 102 obstructive patients. I'm curious: how much consistency between those two groups would be required for you to support a broad HCM label? Suppose the overall result comes out positive, yet the obstructive group, say, turns out inconclusive — would that restrict the indication? Thanks.

Craig Granowitz

executive
#41

Yeah, great question. Normally the approach taken — and we've got experience with this from our heart failure work, where HFrEF and HFpEF were combined in one population — is that we discussed with the FDA and agreed to essentially examine an interaction P-value there. Like all such matters, I think that becomes a review issue within the overall package we submit to the FDA. As long as the two are directionally consistent, based on our experience with the agency, they would likely grant the broad label. That's definitely the spirit in which we approached the FDA when we first submitted this trial for review and comment.

Frank Zhong

analyst
#42

That's really helpful. Thank you, guys.

Mike Exton

executive
#43

Well, thank you all, and I'm sorry about the technical problems with the presentation. Still, I hope you've seen the strong progress the company has achieved in Q3 so far, and we have much more ahead over the coming 6 to 12 months that we think will be quite transformational for the company, across a number of late-stage and earlier catalysts. I really look forward to sharing more with you over the coming weeks and months. Thank you very much, and have a great day.

Operator

operator
#44

Thank you for joining today's programming. You may now disconnect.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Lexicon Pharmaceuticals, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Lexicon Pharmaceuticals, Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Lexicon Pharmaceuticals, Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.